U.S. pharma giant copyright scrapped two experimental weight loss capsules final calendar year—a when-day by day tablet, lotiglipron, because of elevated liver enzymes and a two times-daily tablet, danuglipron, due to sturdy Unintended effects—but CEO Albert Bourla has stated the com